Intrexon, a US-based synthetic biology company, has closed its series E round at $100m, bringing the company’s total capital raised to more than $259m.

New investors took the majority of the round while existing investors, including billionaire Randal Kirk, Intrexon’s executive chairman, through his Third Security venture investment unit, and Sandbox Industries, a venture capital firm that manages health service provider Blue Cross money.

Investment bank Perella Weinberg Partners was Intrexon’s financial adviser and placement agent on the round.

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?